ABUS vs ACIU

Arbutus Biopharma Corporation vs AC Immune SA — Valuation Comparison 2026

ABUS

Biotechnology
Arbutus Biopharma Corporation
Quality
7.0
out of 10
Value Trap
18
SAFE
Price
$4.60
Last close
Models
9/13
Active
VS

ACIU

Biotechnology
AC Immune SA
Quality
4.5
out of 10
Value Trap
35
LOW
Price
$2.75
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ABUS Fair ValueABUS Upside ACIU Fair ValueACIU Upside
Bayesian DCF Intrinsic $1.29 -72.0% $0.44 -83.8%
First Chicago Scenario $4.54 +2.2% $0.45 -84.9%
ML-RIV Intrinsic $0.04 -99.0% $0.09 -96.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ABUS vs ACIU — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ABUS vs ACIU — Which Stock Is More Undervalued?

ABUS scores higher with a 7.0/10 quality rating vs ACIU's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Arbutus Biopharma Corporation (ABUS) and AC Immune SA (ACIU) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ABUS currently trades at $4.60 with a QOC of 7.0/10, while ACIU trades at $2.75 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).